Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

Imagem de Miniatura
Arquivos
art_PEREIRA_Guidelines_for_the_prevention_and_treatment_of_glucocorticoid_2012_eng.PDF (695.7 KB)
art_PEREIRA_Guidelines_for_the_prevention_and_treatment_of_glucocorticoid_2012_por.PDF (681.53 KB)
Citações na Scopus
68
Tipo de produção
article
Data de publicação
2012
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
PAULA, Ana Patricia
ZERBINI, Cristiano
GONCALVES, Helenice
DANOWSKI, Jaime S.
MARQUES NETO, Joao F.
MENDONCA, Laura M. C.
BEZERRA, Mailze C.
Citação
REVISTA BRASILEIRA DE REUMATOLOGIA, v.52, n.4, p.569-593, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Glucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX (R)) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientific evidence and/or expert experience. Method of evidence collection: The bibliographic review of scientific articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glitcocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glitcocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder; Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). Grade of recommendation and level of evidence: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. Objective: To establish guidelines for the prevention and treatment of GIO.
Os glicocorticoides (GC) são prescritos por praticamente todas as especialidades médicas, e cerca de 0,5% da população geral do Reino Unido utiliza esses medicamentos. Com o aumento da sobrevida dos pacientes com doenças reumatológicas, a morbidade secundária ao uso dessa medicação representa um aspecto importante que deve ser considerado no manejo de nossos pacientes. As incidências de fraturas vertebrais e não vertebrais são elevadas, variando de 30%–50% em pessoas que usam GC por mais de três meses. Assim, a osteoporose e as fraturas por fragilidade devem ser prevenidas e tratadas em todos os pacientes que iniciarão ou que já estejam em uso desses esteroides. Diversas recomendações elaboradas por várias sociedades internacionais têm sido descritas na literatura, porém não há consenso entre elas. Recentemente, o Americam College of Rheumatology publicou novas recomendações, porém elas são fundamentadas na FRAX ( WHO Fracture Risk Assessment Tool ) para analisar o risco de cada indivíduo e, dessa maneira, não podem ser completamente utilizadas pela população brasileira. Dessa forma, a Comissão de Osteoporose e Doenças Osteometabólicas da Sociedade Brasileira de Reumatologia, em conjunto com a Associação Médica Brasileira e a Associação Brasileira de Medicina Física e Reabilitação, implementou as diretrizes brasileiras de osteoporose induzida por glicocorticoide (OPIG), baseando-se na melhor evidência cientí fi ca disponível e/ou experiência de experts . Descrição do método de coleta de evidência: A revisão bibliográ fi ca de artigos cientí fi cos desta diretriz foi realizada na base de dados MEDLINE. A busca de evidência partiu de cenários clínicos reais, e utilizou as seguintes palavras-chave (MeSH terms): Osteoporosis, Osteoporosis/chemi- cally induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/ prevention&control, Calcium, Vitamin D, Vitamin D de fi ciency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6–12 anos), adolescence (13–18 anos). Grau de recomendação e força de evidência: A) Estudos experimentais e observacionais de melhor consistência; B) Estudos experimentais e observacionais de menor consistência; C) Relatos de casos (estudos não controlados); D) Opinião desprovida de avaliação crítica, com base em consensos, estudos fisiológicos ou modelos animais. Objetivo: Estabelecer as diretrizes para a prevenção e o tratamento da OPIG.
Palavras-chave
treatment, osteoporosis, glucocorticoid, tratamento, osteoporose, glicocorticoide
URI
https://observatorio.fm.usp.br/handle/OPI/2491
Referências
  1. Adachi JD, 2001, ARTHRITIS RHEUM, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W
  2. Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
  3. Adler RA, 2003, ARCH INTERN MED, V163, P2619, DOI 10.1001/archinte.163.21.2619
  4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, 2001, ARTHRITIS RHEUM, V44, P1496
  5. Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
  6. Baim S, 2008, J CLIN DENSITOM, V11, P75, DOI 10.1016/j.jocd.2007.12.007
  7. Batch JA, 2003, J PAEDIATR CHILD H, V39, P88, DOI 10.1046/j.1440-1754.2003.00083.x
  8. Bianchi ML, 2005, BEST PRACT RES CL RH, V19, P991, DOI 10.1016/j.berh.2005.06.006
  9. Bianchi ML, 2000, ARTHRITIS RHEUM, V43, P1960, DOI 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J
  10. Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
  11. BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402
  12. Braith RW, 2003, J HEART LUNG TRANSPL, V22, P1082, DOI 10.1016/S1053-2498(02)01184-1
  13. Brown JJ, 2005, J PAEDIATR CHILD H, V41, P580, DOI 10.1111/j.1440-1754.2005.00720.x
  14. Buckley LM, 1996, ANN INTERN MED, V125, P961
  15. Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
  16. Chan B, 2006, J CLIN ENDOCR METAB, V91, P2017, DOI 10.1210/jc.2005-2548
  17. Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
  18. Cruse LM, 2006, JCR-J CLIN RHEUMATOL, V12, P221, DOI 10.1097/01.rhu.0000242778.65766.22
  19. de Jong Z, 2004, ARTHRITIS RHEUM, V50, P1066, DOI 10.1002/art.20117
  20. de Nijs RNJ, 2006, NEW ENGL J MED, V355, P675, DOI 10.1056/NEJMoa053569
  21. de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198-004-1614-5
  22. Devogelaer JP, 2006, OSTEOPOROSIS INT, V17, P8, DOI 10.1007/s00198-005-2032-z
  23. Djokanovic Nada, 2008, J Obstet Gynaecol Can, V30, P1146
  24. DUNLOP DJ, 1990, ANN RHEUM DIS, V49, P955, DOI 10.1136/ard.49.11.955-a
  25. Korkor Adel B, 2009, WMJ, V108, P181
  26. Ensrud KE, 2007, J GERONTOL A-BIOL, V62, P744
  27. Franchimont N, 2003, AUTOIMMUN REV, V2, P224, DOI 10.1016/S1568-9972(03)00056-9
  28. Geusens PP, 2004, ANN RHEUM DIS, V63, P324, DOI 10.1136/ard.2003.008060
  29. Gillespie LD, 2009, COCHRANE DB SYST REV, V15
  30. Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
  31. Hodgson Stephen F, 2003, Endocr Pract, V9, P544
  32. HOMIK J, 2000, COCHRANE DB SYST REV
  33. Illidge T M, 1996, Clin Oncol (R Coll Radiol), V8, P257, DOI 10.1016/S0936-6555(05)80667-3
  34. JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602
  35. Kaji H, 2006, ENDOCR J, V53, P27, DOI 10.1507/endocrj.53.27
  36. Kohrt WM, 2004, MED SCI SPORT EXER, V36, P1985, DOI 10.1249/01.MSS.0000142662.21767.58
  37. Langdahl BL, 2009, OSTEOPOROSIS INT, V20, P2095, DOI 10.1007/s00198-009-0917-y
  38. Lau AN, 2010, THER CLIN RISK MANAG, V6, P497, DOI 10.2147/TCRM.S7776
  39. Leufkens HG, 2000, J BONE MIN RES, V15
  40. Levy S, 2009, BONE, V44, P428, DOI 10.1016/j.bone.2008.11.001
  41. Lewiecki EM, 2008, BONE, V43, P1115, DOI 10.1016/j.bone.2008.08.106
  42. Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
  43. Maricic Michael, 2005, Curr Osteoporos Rep, V3, P25, DOI 10.1007/s11914-005-0024-8
  44. Maricic M, 2004, J CLIN DENSITOM, V7, P359, DOI 10.1385/JCD:7:4:359
  45. MINSKER DH, 1993, TOXICOL APPL PHARM, V121, P217, DOI 10.1006/taap.1993.1148
  46. Morin S, 2009, OSTEOPOROSIS INT, V20, P363, DOI 10.1007/s00198-008-0688-x
  47. Munns CFJ, 2004, J BONE MINER RES, V19, P1742, DOI 10.1359/JBMR.040711
  48. National Osteoporosis Society & Royal College of Physicians guidelines working group for Bone and Tooth Society, 2002, GLUC IND OST GUID PR
  49. Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774-004-0596-x
  50. Newman ED, 2006, OSTEOPOROSIS INT, V17, P1428, DOI 10.1007/s00198-006-0149-3
  51. Noguera A, 2003, J PEDIATR ENDOCR MET, V16, P529
  52. Okada Y, 2008, J RHEUMATOL, V35, P2249, DOI 10.3899/jrheum.080168
  53. Ornoy A, 2006, REPROD TOXICOL, V22, P578, DOI 10.1016/j.reprotox.2006.05.009
  54. Patlas N, 1999, TERATOLOGY, V60, P68, DOI 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H
  55. Pongchaiyakul C, 2004, OSTEOPOROSIS INT, V15, P807, DOI 10.1007/s00198-004-1613-6
  56. Poulos P, 2000, CLIN EXP RHEUMAT S21, V18, pS79
  57. Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140-6736(09)60250-6
  58. Reid DM, 2001, CALCIFIED TISSUE INT, V69, P242, DOI 10.1007/s00223-001-1060-8
  59. Richy F, 2004, OSTEOPOROSIS INT, V15, P301, DOI 10.1007/s00198-003-1570-5
  60. Rietbrock S, 2009, QJM-INT J MED, V102, P35, DOI 10.1093/qjmed/hcn130
  61. Ringe JD, 2004, RHEUMATOL INT, V24, P63, DOI 10.1007/s00296-003-0361-9
  62. Roth J, 2007, Z RHEUMATOL, V66, P434, DOI 10.1007/s00393-007-0174-4
  63. Rudge S, 2005, RHEUMATOLOGY, V44, P813, DOI 10.1093/rheumatology/keh538
  64. Saag KG, 2009, ARTHRITIS RHEUM, V60, P3346, DOI 10.1002/art.24879
  65. Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
  66. Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
  67. Sambrook P, 2000, J BONE MINER RES, V15, P1818, DOI 10.1359/jbmr.2000.15.9.1818
  68. SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404
  69. Schmitt NM, 2009, MATURITAS, V63, P34, DOI 10.1016/j.maturitas.2009.03.002
  70. Teucher B, 2008, J BONE MINER RES, V23, P1477, DOI [10.1359/jbmr.080408, 10.1359/JBMR.080408]
  71. Thornton J, 2006, ARCH DIS CHILD, V91, P753, DOI 10.1136/adc.2006.093997
  72. Van Staa T P, 2005, J Bone Miner Res, V20, P1487
  73. Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
  74. Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
  75. van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777
  76. VARONOS S, 1987, CALCIFIED TISSUE INT, V41, P75, DOI 10.1007/BF02555248
  77. Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
  78. Walsh LJ, 1996, BRIT MED J, V313, P344
  79. Winzenberg T, 2006, BMC PUBLIC HEALTH, P6
  80. YARRINGTON JT, 1976, AM J PATHOL, V83, P569
  81. Yeap SS, 2008, J RHEUMATOL, V35, P2344, DOI 10.3899/jrheum.080634

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/41